Latest Content

FDA Approves Tevimbra Plus Chemotherapy For Some With Esophageal Cancer

March 4th 2025, 1:39pm

By Alex Biese

Article

The FDA approved Tevimbra with chemotherapy for adults with unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1.

Expert Explains Safety of Krazati Regimen For Treating Colorectal Cancer

March 3rd 2025, 10:00pm

By Dr. Nataliya Uboha

Video

Krazati plus Erbitux is well tolerated in KRAS G12C-mutant metastatic colorectal cancer, with manageable side effects and less immune suppression.

Immune Checkpoint Inhibitors For Cancer Associated With Psoriasis Risk

March 3rd 2025, 8:00pm

By Alex Biese

Article

Researchers have discovered a strong association between the use of immune checkpoint inhibitors for cancer treatment and a risk of new onset psoriasis.

Accepting My Colon Cancer Diagnosis at A Young Age

March 3rd 2025, 6:00pm

By Carla Deschamps

Article

Being diagnosed with colon cancer at 34 was difficult, but choosing happiness and acceptance helped me find peace through mindfulness, nature and family.

Rusfertide Elicits Promising Responses in Polycythemia Vera

March 3rd 2025, 5:00pm

By Alex Biese

Article

Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted in positive responses.

FDA Accepts Ordspono Resubmission in R/R Follicular Lymphoma Treatment

March 3rd 2025, 4:00pm

By Ryan Scott

Article

The FDA has accepted the resubmission of the BLA of Ordspono for review in relapsed/refractory follicular lymphoma following previous systemic therapy.

My Journey With Squamous Cell Carcinoma

March 3rd 2025, 2:00pm

By John H. Clark III

Article

A patient shares his experience with a squamous cell carcinoma diagnosis, treatment and recovery.

First Patient With Small Cell Lung Cancer Dosed With Peluntamig

March 2nd 2025, 7:00pm

By Spencer Feldman

Article

The first patient with small cell lung cancer has been dosed in a trial of peluntamig (PT217) combined with chemotherapy.

First Patient Dosed With HLD-0915 for mCRPC in First-In-Human Trial

March 2nd 2025, 3:00pm

By Alex Biese

Article

The first patient has been dosed in a first-in-human clinical trial evaluating HLD-0915 for metastatic castration-resistant prostate cancer.

Breaking Down The Results of The ALPHA/ALPHA2 Study in Large B-Cell Lymphoma

March 1st 2025, 7:00pm

By Dr. Frederick L. Locke

Video

Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.

Camizestrant Combo Improves Progression Time in HR+/HER2– Breast Cancer

March 1st 2025, 3:00pm

By Ryan Scott

Article

Camizestrant with a CDK 4/6 inhibitor had a statistically significant and clinically meaningful improvement in PFS in HR+/HER2– advanced breast cancer.

Cema-Cel Has Durable Responses in in Relapsed/Refractory Large B-Cell Lymphoma

February 28th 2025, 10:00pm

By Ryan Scott

Article

Treatment with the CAR T-cell therapy cema-cel demonstrated durable responses in patients with relapsed/refractory large B-cell lymphoma.

Chemoradiation Benefits for Cervical Cancer May Decline After Age 80

February 28th 2025, 8:00pm

By Spencer Feldman

Article

Chemoradiation improves survival in cervical cancer patients, but benefits may decline after age 80, according to a study using SEER data.

A Second Chance I Never Knew I Had After Lymphoma

February 28th 2025, 6:00pm

By Linda Cohen

Article

A year ago, I was told my lymphoma had worsened, but a miraculous turn of events spared me from aggressive chemotherapy, making me grateful for each day of life.

An Expert Highlights His Key Takeaways From The 2025 ASCO GU Symposium

February 28th 2025, 5:00pm

By Dr. Chandler Park

Video

Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.